By Daniella Parra
Jeito Capital said it is leading a €132 million oversubscribed Series B funding round in Azafaros, a clinical-stage biotech company developing treatments for rare lysosomal storage disorders.
Azafaros, founded in 2018 and rooted in Dutch academic research, is advancing nizubaglustat, a first-in-class dual-acting drug targeting conditions like Niemann-Pick Type C and GM1/GM2 gangliosidoses, they said.
“Azafaros has the potential to develop new efficient, safe and tolerable therapeutic options for young patients suffering from progressive debilitating and even fatal rare metabolic disorders that generates very high expectations.” said Dr Rafaèle Tordjman, Founder and CEO of Jeito Capital. “We look forward to supporting the talented Azafaros team with our collective expertise to accelerate its pivotal clinical developments to go faster to patients.”
Contact: